IPO - Lexeo Therapeutics, Inc.

Form Type: S-3

Filing Date: 2025-06-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525140744

Filing Summary: Lexeo Therapeutics, Inc., a Delaware corporation, is filing a registration statement under the Securities Act of 1933 for the issuance of up to 20,840,394 shares of its common stock, which includes shares issuable upon the exercise of pre-funded and common warrants held by selling stockholders. The offering may commence at any time after the registration statement becomes effective. The shares were part of a private placement that occurred on May 28, 2025, where Lexeo issued 20,790,120 outstanding shares, pre-funded warrants for 6,963,556 shares, and common warrants for 13,876,838 shares for a total of approximately $80 million. The registration process allows selling stockholders to resell their shares without involvement from Lexeo, which will not receive any proceeds from the sales of shares by the stockholders but will receive proceeds from any cash exercises of the warrants. The document emphasizes risk factors related to investing in its securities and outlines Lexeo's emerging growth company status, which allows it to comply with reduced reporting obligations. Key clinical details regarding their therapeutic pipeline targeting cardiovascular diseases, including LX2006 and LX2020, are also included, emphasizing advancements in treatment candidates and an alignment with the FDA on registrational plans.

Form Type: 424B5

Filing Date: 2025-03-24

Corporate Action: Ipo

Type: New

Accession Number: 000119312525060883

Filing Summary: Lexeo Therapeutics, Inc. is conducting a public offering of its common stock with an aggregate offering price of up to $75 million. The Sales Agreement with Leerink Partners LLC allows the company to sell shares on an ‘at-the-market’ basis, which means no specific number is guaranteed. As of the closing price on March 21, 2025, the shares are priced at $2.71 each. The company aims to use the proceeds from this offering for general corporate purposes, which could include clinical trials, research and development, and potentially acquisitions. Lexeo is a clinical-stage genetic medicine company focusing on cardiovascular diseases, with key products in trials, including LX2006 and LX2020, both targeting serious heart conditions. The document highlights the risks involved in investing in their securities while also noting the company's status as an emerging growth company, which significantly eases certain reporting requirements. There is no state or SEC approval regarding the adequacy of this prospectus supplement. The risks of the investment include potential dilution of stock value and reliance on management's discretion for the use of offering proceeds.